Published in Cancer Weekly, July 26th, 2005
The capital increase is expected to raise approximately 100 million euros (U.S. $121 million). A "green shoe" of up to 15% of the amount raised can be exercised by HSBC, which is the sole bookrunner on the transaction.
The funds raised will be used to further the continued research, development and commercialization of cancer products being developed by PharmaMar, Zeltia's biotech subsidiary.
PharmaMar is a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.